Mark Scarupa, MD

Unless otherwise indicated, this information has been self-reported and has not been verified by the Board of Medicine.

None Reported

Johns Hopkins University Medical Center
Rank: Instructor
Years: 2004-2023

Study design, baseline, and 24-week open-label results from XTEND-CIU: a phase IV, multi center, ranomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of omalizumab in patients with chronic idiopathic urticaria
Journal of the American Academy of Dermatology
2018, 78(4): 793-795
Date: 12 2018

Validation of inducible basophil biomarkers: Time, temperature and transportation.
Cytometry
2021, 100: 632-644
Date: 01 2021